KnowEnG Center Annual NIH Site Visit and External Advisory Council Meeting, April 27-28
The KnowEng Annual NIH Site Visit and External Advisory Council Meeting will be held April 27-28, 2017 at the Carle R. Woese Institute for Genomic Biology. Details about the program and registration information can be found here.
Cancer Community at Illinois Faculty Seminar Series
The Cancer Community at Illinois Faculty Seminar Series continues with a session the first week of April.
Today! Thursday, April 6 | 3:00 p.m. - 4:30 p.m.
Health Care Engineering Systems Center (HCESC), Room 1232
(HCESC is in the lower level of the North Campus Parking Deck Building at 1206 W Clark Street, Urbana, IL)
This month's speakers and talk titles are:
- Rohit Bhargava (Bioengineering)
- “Chemical Imaging for Digital Molecular Pathology”
- Rex Gaskins (Animal Sciences)
- “Microbial Sulfur Metabolism and Colorectal Cancer Risk”
- Edward Roy (Pathology)
- “Immunotherapy of Gliomas”
- T. Kesh Kesavadas (HSESC)
- “Precision Surgery Through Robotics”
Advance registration was requested, but seats are still available so we hope to see you this afternoon.
HHMI Investigator Panel, April 19
The Office of the Vice Chancellor for Research is sponsoring a HHMI Investigator Panel on Wednesday, April 19, 2017. The Howard Hughes Medical Institute (HHMI) will appoint up to 20 new biomedical researchers for up to 7 years through a national open competition. (It is not a limited submission.) The competition is open to basic researchers and physician-scientists who bring innovative approaches to the study of biological problems in biomedical disciplines, plant biology, evolutionary biology, biophysics, chemical biology, biomedical engineering and computational biology.
April 19, 2017, Wednesday 10:00 AM
Room 350 B at ERML – Edward R. Madigan Labs
- Martin Burke, Professor of Chemistry, Howard Hughes Medical Institute Early Career Scientist
- Jeffrey S. Moore, Murchison-Mallory Professor of Chemistry, Howard Hughes Medical Institute Professor
- Wilfred A. van der Donk, Richard E. Heckert Endowed Chair in Chemistry Howard Hughes Medical Institute Investigator
For more information about the investigator competition please visit the HHMI website.
RSVP for the April 19 CSTAR Reception
The CSTAR program will be holding a reception April 19, 2017. This is a great opportunity for faculty, students, and physicians to learn more about the exciting research happening in the CSTAR program.
Carle and Illinois Reception
April 19, 2017
4:00 - 6:00 p.m.
Mills Breast Cancer Center
Carle Houseworth Conference Center (2nd floor)
Please RSVP by Noon on April 14, 2017.
Carle Cancer Research Update Meeting
Join the discussion at the Carle Cancer Research Update Meeting. This week Evi Llabani, PhD candidate and CSTAR participant, will present “Personalized Treatment Strategy for Metastatic Breast Cancer Patients.” Lunch is not served, but you are welcome to bring your own lunch if you would like.
"Personalized Treatment Strategy for Metastatic Breast Cancer Patients"
Evi Llabani, PhD Candidate, CSTAR participant
Department of Chemistry, University of Illinois
April 7, 2017
Noon-12:30 p.m. CST
Carle Cancer Center/MBCI-2nd Floor
Houseworth Conference Room
| ||Elsa Pardee|
Pardee Foundation RFP for Cancer Research
The Elsa U. Pardee Foundation was established in 1944 under the terms of the will of Mrs. Elsa U. Pardee, whose life was taken by cancer on October 2, 1944. She directed that her bequest be used to support research in the field of cancer and to provide to others the advantages of new knowledge and techniques for the treatment of this related group of disabling and frequently lethal diseases. To that end, the Pardee Foundation provides support to investigators at nonprofit institutions in the United States proposing research focused on identifying new treatments or cures for cancer.
The Foundation particularly encourages grant applications for a one year period which will allow establishment of capabilities of new cancer researchers, or new cancer approaches by established cancer researchers. It is anticipated that this early stage funding by the Foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified. By design, there are no limits set on the grant amount that can be requested. It must be reasonably and clearly supported by the scope of the project outlined in the application.
Applications requesting more than 15 percent overhead usually are not considered. Papers verifying nonprofit status and relevant human subject and experimental animal treatment approvals from the recipient institution will be requested prior to project initiation. A final report summarizing financial expenditure and research achievement is required. Past awards have ranged from $136,000 to $199,000. Deadlines: April 30, 2017 (reviewed in May) August 31, 2017 (reviewed in September) Link to Complete RFP Complete RFP.
Deadline: June 16, 2017.
| ||Melanoma cells move quickly, extending cables to reel in other cells and form tumors. The panels show how individual melanoma cells came together to build a tumor in just four hours. Credit: David Soll laboratory, University of Iowa|
Team identifies drugs that halt skin cancer metastasis in lab tests
Science Daily — There's a reason why melanoma, the most serious type of skin cancer, is so aggressive. You just need to watch the cells in action. Researchers at the University of Iowa did just that, documenting in real time and in 3-D how melanoma cells form tumors. The cells waste no time finding their cancerous cousins, slashing their way through a lab-prepared gel to quickly join other melanoma cells and form tumors. The findings were published online in the journal PLOS One.
Biology professor David Soll and his team used unique computer-assisted 3-D reconstruction software to chronicle how both breast tissue cancer cells and melanoma cells form tumors. The group found the two cancers act similarly in the joining stages of tumor formation. With that knowledge, they screened more than four dozen monoclonal antibodies— unique agents that can stop cells from growing or forming tumors and can be mass produced —before finding two that block tumor creation in both types of cancer.”
Read the full story here.
Visit our Events Calendar for a complete list of upcoming cancer-related activities and events.